How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State www.nytimes.com/interactive/...

Exploring the burden of cancer in metastatic renal cell carcinoma (mRCC) 📊🧬 This study sheds light on the impact of mRCC on patients & healthcare systems. Don’t miss these key insights @ascocancer.bsky.social #GU25!

#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25

On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social

Why is funding NIH so important? Listen to the Good News About Cancer w/ @charlesryanmd.bsky.social @mskcancercenter.bsky.social @drkarenknudsen.bsky.social & Dr. Morgans. Also amazing news about decline in lung cancer in Puerto Rico b/c of public health measures! podcasts.apple.com/us/podcast/4...

Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...

Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with ORR of 41% DCR 90% 50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor @MSKCancerCenter #ASCOGU #GU25

@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25

Watching #BCR session @asco #GU25 it is very clear there is a drive to treat #BCR asap esp w/+ #PSMA But there is no data supporting a curative strategy & in that context deferring therapy max’ing #QOL is quite reasonable given JHU MFS data below ascopubs.org/doi/10.1200/...

Announcing the ASCO Genitourinary Cancers Symposium Featured Voices! Follow along for a range of expert insights and join the conversation using the official hashtag: #GU25 Not yet registered? There’s still time to join us in person or online: brnw.ch/21wQAYk

As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer www.nature.com/articles/s41...

SUPER BOWL CHAMPIONS! THIS ONE’S FOR YOU PHILLY!

Trump & Musk are making massive cuts to the National Institutes of Health. I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.

Both ERA Commons and NIH Reporter are currently unavailable.

🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25: - Bladder Ca - Prostate Ca - RCC *Join us LIVE* 📅 Date: Feb 12, 2025 ⏰ Time: 6:00-8:00PM 📝 bit.ly/guaio25 #OncSky #MedSky #gusm #Oncology #Cancer #CanSky

In the ESOPEC trial, researchers evaluated whether perioperative chemotherapy improves overall survival as compared with preoperative chemoradiotherapy in patients with resectable esophageal adenocarcinoma. Full trial results and Plain Language Summary: nej.md/4apWlo5 #MedSky #Oncology

Hello, #MedSky community! We’re excited to begin our Bluesky journey. Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma @fda.gov #oncology www.onclive.com/view/fda-gra...

Hello out there scientists. If you're having meetings or grants or anything else impacted by freeze of NSF meetings, please feel free to reach out to me to share your story. Signal: thealexknapp.79 Email: [email protected]

🎉 EMA celebrates its 3️⃣0️⃣th anniversary highlighting its evolving role at the centre of the EU assessing & authorising safe, high-quality medicines for 450 million people & countless animals in Europe. Learn more about EMA’s key achievements over the past 30 years: www.ema.europa.eu/en/news/ema-...

This is huge. The European equivalent to the FDA has said enough to the propaganda machine X. Others will follow. #medsky #oncosky www.reuters.com/world/europe...

The clearest sign of intellectual chemistry isn’t agreeing with someone. It’s enjoying your disagreements with them. Harmony is not the combination of identical sounds. It’s the pleasing arrangement of different tones, voices, or instruments. Creative tension makes beautiful music.

Creating a bladder & kidney cancer starter pack of friends and colleagues here in @bsky.app! Please comment if you want to be added! bsky.app/start/did:pl... @pgrivasmdphd.bsky.social @drchoueiri.bsky.social @erplimackmd.bsky.social @davidaggen.bsky.social @pcvblack.bsky.social

Roughly 6,000 readers answered our poll, with many declaring that Bluesky was nicer, kinder and less antagonistic to science than X https://go.nature.com/42tH8Ai

Thanks Esther for this explainer, I hope it reaches the right audience. The complexity of health research is not widely appreciated, yet the diseases scientists are trying to cure affect us all.

Remembering Amy Babler: A fearless Advocate for Cancer Awareness and Communications @foxchasesurgonc.bsky.social oncodaily.com/blog/amy-bab... #Cancer #OncoDaily #Oncology #Medicine #Health

Thrilled to announce that my dear friend and colleague, Jay Simhan, MD, FACS, has been named Chair of Urology at Temple University Hospital! I’m thrilled to partner as two departments under the Fox Chase-Temple Urologic Institute to elevate our already world-class program to even greater heights!

This Christmas and every year I remember my current and past patients with ornaments on our tree. Have been fortunate to care for thousands in my ten year career in oncology. Hope to help thousands more in the years to come. 🎄🕯️

Can some MIBC patients safely skip cystectomy? In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%. @oncoalert.bsky.social @oncbrothers.bsky.social @erplimackmd.bsky.social doi.org/10.1200/JCO-...

#PSMA imaging is showing #ProstateCancer in a WAY never seen before but it is unlikely to be showing Prostate Cancer that we have never encountered before The presumption of the latter leads to aggressive therapy which may not be required More data on this coming from @theNCI

Another memorable night. #SUO24 reunion (credit @urocorrea.bsky.social ) bringing together the extended FCCC family, and introducing future YUO/SUO colleagues. To alums who couldn’t make it, we hope to see you #AUA25 in Vegas, baby!

Percentage of available positions that filled in yesterday’s fellowship match.

Stayed active during 17-hour flight from SEA->Singapore :-) Looking forward to present TROPiCS04 phase 3 trial data at #ESMOASIA on Dec 7 ~10am local time discussed by Dr. Friedlander @oncoalert.bsky.social @achoud72.bsky.social @erplimackmd.bsky.social @valdesan.bsky.social @fredhutch.bsky.social

🥳🥳🥳 The final results of the 2024 #HCWvsHunger competition have been confirmed & certified! Most exciting: #MedTwitter & supporters have raised a total of $3,155,425 to fight #FoodInsecurity since the first annual competition in 12/20!! /1 cc @tmprowell.bsky.social @shematologist.bsky.social

Q&A—how to apply ctDNA in medical management—differing approaches by the panel reflects lack of existing data on whether ready for prime time and if it shld lead to a change in care compared to using clinical/path alone. #blcsm #SUO24

Join the conversation on all things #bladdercancer #kidneycancer #prostatecancer and help grow the GU Oncology Starter Pack go.bsky.app/6NdMXmY

Let's share some love for @theaacr.bsky.social here on Bluesky and get them more followers, more engagement, and more awareness of programs like the SSP: @rickbuck.bsky.social @ashi-w.bsky.social @johannajoyce.bsky.social @erplimackmd.bsky.social @pauladbos.bsky.social @anirbanmaitra.bsky.social

De-escalation (of numbers of drugs as well as dosages) is shaping up to be a major theme in #oncology, beginning with @sabcs.bsky.social coming up next month. Colleagues in #breastcancer leading the way, maybe more to come for GI cancers at #GI25, and even more at #ASCO25?

ASCO annual meeting 2025 abstract submitter open - closes Jan 28th. To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)! Apply for a waiver when you submit an abstract conferences.asco.org/am/abstract-...

ICYMI: *30* year outcomes from SPCG-4 dx.doi.org/10.1056/NEJM... RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

GU starter pack… started! Let me know if you want to be added. go.bsky.app/DtoXvaD #Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter

I’m going to the Nobel prize celebrations in Stockholm in 2 weeks along w/100 other Rosetta contributors. I figure a few things we contributed were helpful in making it work in the pre-RF-diffusion days. Backbone-dependent scoring/sampling of rotamers helped design work, I think. Just got a new tux!

Join the conversation on all things #bladdercancer #kidneycancer #prostatecancer and help grow the GU Oncology Starter Pack go.bsky.app/6NdMXmY

Old Twitter” refers to the platform’s earlier role as a hub where scientists could talk to one another, distribute and discuss preprints and published papers and communicate their research to the public. @tmprowell.bsky.social @erikahamilton9.bsky.social www.science.org/content/arti...

Team lunch at Fox Chase 🙌 @dytcmd.bsky.social, you missed this one! @urocroll.bsky.social, nice hat!

Active surveillance for intermediate-risk prostate cancer rose from 5% in 2010 to 12.3% in 2020. Most common in GG1 cases (53.8% by 2020). PSA and GG remain key factors. #ProstateCancer #ActiveSurveillance #Oncology #CancerResearch @oncoalert.bsky.social

Ok Not really sure what I’m doing but this #ProstateCancer starter pack has been created It is meant to be INclusive so please let me know if you know anyone who wants so “join” @asharpmedonc.bsky.social @nimasharifimd.bsky.social @alison-tree.bsky.social @profiand.bsky.social go.bsky.app/ANw3D3j

Responders to therapy do well. The real quandary is there something that is required to be done for #ProstateCancer pts w/out optimal response. Should be cautious about suboptimal responders abandoning effective therapy too quickly. Additional investigation is required. #TITAN

I've been in 7 #MetastaticBreastCancer treatment #ClinicalTrials and no one yet has shared the published results directly with me (I found articles via patient grps and that old place X). #Oncsky It really should be common practice and the UK's NHS agrees: www.hra.nhs.uk/planning-and...